In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Infliximab Suppresses TNF-α Induced Inflammatory Phenotype in Cerebral Vascular Smooth Muscle Cells: Implications for Cerebral Aneurysm Formation

    Final Number:
    184

    Authors:
    Muhammad S Ali MD; Robert M. Starke MD MSc; Pascal Jabbour MD; Stavropoula I. Tjoumakaris MD; L. Fernando Gonzalez MD; Robert H. Rosenwasser MD, FACS, FAHA; Aaron S. Dumont MD

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Cerebral Aneurysm rupture results in significant morbidity and mortality. TNF-a has been associated with cerebral aneurysms, but potential mechanisms have not been established, and its role in phenotypic modulation is unknown. Therapy targeting TNF-a may represent a novel treatment strategy for cerebral aneurysms.

    Methods: Cultured cerebral VSMC were incubated with increasing concentrations of TNF-a (5 ng/ml and 50 ng/ml) for 24 hours. Cerebral aneurysm induction surgery was performed in rats. Animal were euthanized at 4 weeks for qPCR and immunohistochemical analysis of the circle of Willis. Animals undergoing aneurysm induction and Infliximab (5mg/kg) treatment were compared to animals undergoing aneurysm induction alone and untreated controls.

    Results: In vitro experiments demonstrated suppression of differentiation markers and induction of pro-inflammatory genes. In vivo, TNF-a mRNA and protein expression was significantly elevated following aneurysm induction compared to untreated controls. Expression of inflammatory markers including chemokines (MCP1 and VCAM1), transcription factors (NF-?B, KLF4), matrix remodeling proteins (MMP-2 & 3), IL-1ß and iNOS was also increased. Furthermore, aneurysm induction resulted in phenotypic modulation by decreasing expression of SMC differentiation marker gene SM-a-Actin. Treatment with Infliximab significantly suppressed TNF-a activity, inhibited expression of inflammatory markers, and decreased the number of CD68+ cells during aneurysm formation. Infliximab also reversed phenotypic modulation in vascular SMC following aneurysm induction.

    Conclusions: ??F-a plays a pivotal role in SMC phenotypic modulation with induction of pro-inflammatory genes and inhibition of SMC differentiation marker genes both in cultured cerebral vascular SMC and in vivo following cerebral aneurysm induction. Infliximab promotes anti-inflammatory effects in cerebral vessels by inhibiting TNF-a and suppressing a pro-inflammatory cascade, which has important implications for the mechanisms behind intracranial aneurysm formation and potential therapeutic options.

    Patient Care: Current understanding of aneurysm biology is inadequate. Better understanding the underlying pathology will help us develop non or minimally invasive treatment options for patients.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) the role of cerebral vascular smooth muscle (VSMC) phenotypic modulation in aneurysm formation and progression 2) the role of tumor necrosis factor-alpha in inducing phenotypic modulation in VSMC and inflammatory up-regulation 3) role of Infliximab (a specific TNFa inhibitor) in suppressing inflammatory up-regulation induced by TNFa in vivo

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy